Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 40

Sort by

Sort Order Select

Journal Articles

BCMA Mutational Screening Reveals Differential Cytotoxic Activity between T-Cell Engagers in Preclinical Co-Culture Models

Vinidhra Sridharan, Hsiling Chiu, Shirong Li, Chad C. Bjorklund, Anita K. Gandhi, Patrick R. Hagner

Blood (2024) 144 (Supplement 1): 4650.

https://doi.org/10.1182/blood-2024-211024

Published: 2024

Journal Articles

Development of Anti-Amyloid 11-1F4- CAR Phagocytes for Treatment of AL Amyloidosis

Jing Fu, Huihui Ma, Shirong Li, Michael Sang Hughes, Gavreel Kalantarov, Guifen Liu, Markus Mapara, Suzanne Lentzsch

Blood (2024) 144 (Supplement 1): 360.

https://doi.org/10.1182/blood-2024-202091

Published: 2024

Journal Articles

Synergistic Anti-Tumor Effects in RAS Mut Multiple Myeloma By Targeting MAP4K2 and RAS Pathways

Jing Fu, Shirong Li, Guifen Liu, Huihui MA, Christophe Marcireau, Markus Mapara, Suzanne Lentzsch

Blood (2023) 142 (Supplement 1): 6618.

https://doi.org/10.1182/blood-2023-190740

Published: 2023

Journal Articles

Checkpoint Inhibitor PD-1H/VISTA Affects Myeloma Bone Disease By Osteoclast Cytoskeleton Remodeling

Jing Fu, Shirong Li, Huihui MA, Lewis M Brown, Markus Mapara, Suzanne Lentzsch

Blood (2023) 142 (Supplement 1): 6610.

https://doi.org/10.1182/blood-2023-189820

Published: 2023

Journal Articles

The Novel Role of Checkpoint Inhibitor PD-1H/VISTA in Osteoclast Cytoskeleton Regulation and Multiple Myeloma Bone Disease

Jing Fu, Shirong Li, Huihui Ma, Jun Yang, Lewis M Brown, Gabriel M. Pagnotti, Stephen J. Weiss, Markus Y. Mapara, Suzanne Lentzsch

Blood (2022) 140 (Supplement 1): 9930–9932.

https://doi.org/10.1182/blood-2022-169921

Published: 2022

Journal Articles

MAP4K2 Inhibition Reinforces the Iberdomide Sensitivity in MM Cells By Inducing IKZF1 Degradation through a CRBN Independent Mechanism

Shirong Li, Jing Fu, Jun Yang, Huihui Ma, Markus Y. Mapara, Christophe Marcireau, Suzanne Lentzsch

Blood (2022) 140 (Supplement 1): 4224–4225.

https://doi.org/10.1182/blood-2022-168314

Published: 2022

Journal Articles

MAP4K2 Silencing Overcomes IMiDs-Resistance in Multiple Myeloma

Shirong Li, Jing Fu, Jun Yang, Huihui Ma, Markus Y. Mapara, Christophe Marcireau, Suzanne Lentzsch

Blood (2021) 138 (Supplement 1): 2662.

https://doi.org/10.1182/blood-2021-151844

Published: 2021

Journal Articles

The Novel Role of Checkpoint Inhibitor PD-1H/VISTA in Osteoclast Activation and Multiple Myeloma Bone Disease

Jing Fu, Shirong Li, Huihui Ma, Jun Yang, Lewis M Brown, Gabriel M. Pagnotti, Stephen J. Weiss, Markus Y. Mapara, Suzanne Lentzsch

Blood (2021) 138 (Supplement 1): 1606.

https://doi.org/10.1182/blood-2021-145599

Published: 2021

Journal Articles

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma

Shirong Li, Jing Fu, Jun Yang, Huihui Ma, Divaya Bhutani, Markus Y. Mapara, Christophe Marcireau, Suzanne Lentzsch

Blood (2021) 137 (13): 1754–1764.

https://doi.org/10.1182/blood.2020006334

Published: 2021

Includes: Supplemental data

Journal Articles

Gck Inhibition Is a Novel Therapeutic Strategy for RAS Mutated Multiple Myeloma and Overcomes Resistance to IMiDs

Shirong Li, Jing Fu, PhD, Jun Yang, MS, Markus Y Mapara, MD PhD, Christophe Marcireau, Suzanne Lentzsch, MD PhD

Blood (2020) 136 (Supplement 1): 24.

https://doi.org/10.1182/blood-2020-143418

Published: 2020

Journal Articles

Checkpoint Inhibitor PD-1H/VISTA Mediates MMP-13 Induced Osteoclast Activation and Multiple Myeloma Bone Disease

Jing Fu, PhD, Shirong Li, Huihui Ma, MD PhD, Jun Yang, MS, Gabriel M. Pagnotti, PhD, Stephen J. Weiss, MD PhD, Markus Y Mapara, MD PhD, Suzanne Lentzsch, MD PhD

Blood (2020) 136 (Supplement 1): 15–16.

https://doi.org/10.1182/blood-2020-142528

Published: 2020

Journal Articles

Gck Kinase Activity Is Critical for RAS Mutated Myeloma - a Potential Treatment Approach for Targeting Specific Mutations

Shirong Li, PhD, Jing Fu, PhD, Xiaoming Xu, PhD, Shixian Deng, PhD, Markus Y Mapara, MD PhD, Christophe Marcireau, Suzanne Lentzsch, MD PhD

Blood (2019) 134 (Supplement_1): 1813.

https://doi.org/10.1182/blood-2019-129531

Published: 2019

Journal Articles

Checkpoint Inhibitor PD-1H/VISTA Functions As MMP-13 Receptor on Osteoclasts and Mediates MMP-13 Induced Osteoclast Activation in Multiple Myeloma

Jing Fu, PhD, Shirong Li, PhD, Chen Yang, Lewis M Brown, PhD, Stephen J Weiss, MD PhD, Charles G Drake, MD PhD, Markus Y. Mapara, MD PhD, Suzanne Lentzsch, MD PhD

Blood (2019) 134 (Supplement_1): 3072.

https://doi.org/10.1182/blood-2019-129177

Published: 2019

Journal Articles

The Inhibition of Gck Affect MAPK Cascade in Multiple Myeloma

Shirong Li, Jing Fu, PhD, Shixian Deng, Hsin S Wang, Xiaoming Xu, Markus Y Mapara, MD PhD, Donald W Landry, Suzanne Lentzsch, MD PhD

Blood (2018) 132 (Supplement 1): 3202.

https://doi.org/10.1182/blood-2018-99-117557

Published: 2018

Journal Articles

Germinal Center Kinase As a Therapeutic Target in Multiple Myeloma

Shirong Li, Jing Fu, PhD, Hsin S Wang, Xiaoming Xu, Shixian Deng, Donald W Landry, Markus Y Mapara, MD PhD, Suzanne Lentzsch, MD PhD

Blood (2017) 130 (Supplement 1): 1795.

https://doi.org/10.1182/blood.V130.Suppl_1.1795.1795

Published: 2017

Journal Articles

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies

Changchun Deng, Mark R. Lipstein, Luigi Scotto, Xavier O. Jirau Serrano, Michael A. Mangone, Shirong Li, Jeremie Vendome, Yun Hao, Xiaoming Xu, Shi-Xian Deng, Ronald B. Realubit, Nicholas P. Tatonetti, Charles Karan, Suzanne Lentzsch, David A. Fruman, Barry Honig, Donald W. Landry, Owen A. O’Connor

Blood (2017) 129 (1): 88–99.

https://doi.org/10.1182/blood-2016-08-731240

Published: 2017

Includes: Supplemental data

Journal Articles

Silencing c-Myc Translation As a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies

Changchun Deng, MD PhD, Mark Lipstein, Luigi Scotto, PhD, Xavier O Jirau Serrano, B.S., Michael Mangone, PhD, Shirong Li, PhD, Jeremie Vendome, PhD, Yun Hao, Xiaoming Xu, Xiaoping Liu, MD PhD, Ipsita Pal, PhD, Shi-Xian Deng, PhD, Nicholas P. Tatonetti, PhD, Suzanne Lentzsch, MD PhD, Barry Honig, PhD, Donald Landry, MD PhD, Owen A. O'Connor, MD PhD

Blood (2016) 128 (22): 291.

https://doi.org/10.1182/blood.V128.22.291.291

Published: 2016

Journal Articles

SYK-Inhibitor Bay 61-3606 Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma Cells Independent of SYK Inhibitory Effects but Via Degradation of IKZF1/3

Shirong Li, PhD, Jing Fu, PhD, Jing Wu, MD PhD, Markus Y Mapara, MD PhD, Suzanne Lentzsch, MD PhD

Blood (2016) 128 (22): 4477.

https://doi.org/10.1182/blood.V128.22.4477.4477

Published: 2016

Journal Articles

Interferon Gamma (IFNγ)/STAT1 Signaling in Host Antigen Present Cells Suppresses MHC Class II-Dependent Presentation of Self-Antigens and Development of Graft Versus Host Disease (GVHD)

Caisheng Lu, MD PhD, Huihui Ma, MD, PhD, Liangsong Song, MD, PhD, Shirong Li, PhD, Suzanne Lentzsch, MD PhD, Markus Y Mapara, MD PhD

Blood (2016) 128 (22): 2147.

https://doi.org/10.1182/blood.V128.22.2147.2147

Published: 2016

Journal Articles

IKZF1 Mutation Mediate Resistance to IMiDs in Human Hematopoietic Stem Cells

Shirong Li, PhD, Jing Fu, PhD, Jing Wu, MD PhD, Markus Y Mapara, MD PhD, Suzanne Lentzsch, MD PhD

Blood (2015) 126 (23): 3003.

https://doi.org/10.1182/blood.V126.23.3003.3003

Published: 2015

NARROW

BCMA Mutational Screening Reveals Differential Cytotoxic Activity between T-Cell Engagers in Preclinical Co-Culture Models

Development of Anti-Amyloid 11-1F4- CAR Phagocytes for Treatment of AL Amyloidosis

Synergistic Anti-Tumor Effects in RAS Mut Multiple Myeloma By Targeting MAP4K2 and RAS Pathways

Checkpoint Inhibitor PD-1H/VISTA Affects Myeloma Bone Disease By Osteoclast Cytoskeleton Remodeling

The Novel Role of Checkpoint Inhibitor PD-1H/VISTA in Osteoclast Cytoskeleton Regulation and Multiple Myeloma Bone Disease

MAP4K2 Inhibition Reinforces the Iberdomide Sensitivity in MM Cells By Inducing IKZF1 Degradation through a CRBN Independent Mechanism

MAP4K2 Silencing Overcomes IMiDs-Resistance in Multiple Myeloma

The Novel Role of Checkpoint Inhibitor PD-1H/VISTA in Osteoclast Activation and Multiple Myeloma Bone Disease

Targeting the GCK pathway: a novel and selective therapeutic strategy against RAS-mutated multiple myeloma

Gck Inhibition Is a Novel Therapeutic Strategy for RAS Mutated Multiple Myeloma and Overcomes Resistance to IMiDs

Checkpoint Inhibitor PD-1H/VISTA Mediates MMP-13 Induced Osteoclast Activation and Multiple Myeloma Bone Disease

Gck Kinase Activity Is Critical for RAS Mutated Myeloma - a Potential Treatment Approach for Targeting Specific Mutations

Checkpoint Inhibitor PD-1H/VISTA Functions As MMP-13 Receptor on Osteoclasts and Mediates MMP-13 Induced Osteoclast Activation in Multiple Myeloma

The Inhibition of Gck Affect MAPK Cascade in Multiple Myeloma

Germinal Center Kinase As a Therapeutic Target in Multiple Myeloma

Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies

Silencing c-Myc Translation As a Therapeutic Strategy through Targeting PI3K Delta and CK1 Epsilon in Hematological Malignancies

SYK-Inhibitor Bay 61-3606 Induces Cell Cycle Arrest and Apoptosis in Multiple Myeloma Cells Independent of SYK Inhibitory Effects but Via Degradation of IKZF1/3

Interferon Gamma (IFNγ)/STAT1 Signaling in Host Antigen Present Cells Suppresses MHC Class II-Dependent Presentation of Self-Antigens and Development of Graft Versus Host Disease (GVHD)

IKZF1 Mutation Mediate Resistance to IMiDs in Human Hematopoietic Stem Cells

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only